Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Clinical Data For Tesetaxel, A Leading Oral Taxane, Show Anticancer Activity And Acceptable Safety In Ongoing Study
Genta Incorporated (OTCBB: GNTA.OB) announced preliminary results from its ongoing clinical study of tesetaxel, a leading oral taxane in the Company"s investigational drug portfolio. The new data show a favorable safety profile with a low incidence of serious adverse events, along with objective responses that have been observed at less than the maximally tolerated dose (MTD). The data are featured in a presentation today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL.

Recent Releases: Polio Eradication; Chagas Disease Discovery Anniversary; River Blindness; Malaria Tools; Childhood Malnutrition
MMWR Examines Polio Eradication In India
News of the day
Northamptonshire Animal Feed Company Fined After Worker Falls From Height
The Health and Safety Executive (HSE) is reminding employers of their duties to the safety of staff following an incident in Kettering where an employee fell six foot and suffered serious injury.
Diagnostics

Longer, Stronger HIV Drug Regimen For Breastfeeding Women Cuts Mother-To-Child Transmission Rate, Study Finds

"HIV infection rates among babies are significantly cut when mothers are given prolonged ARV treatment during breastfeeding," according to findings released at the International AIDS Society conference in Cape Town, South Africa on Wednesday, Reuters reports. According to Reuters, "Key findings from the study showed that a stronger drug cocktail administered over a longer period reduced the risk of mother-to-child HIV transmission compared with the current WHO-recommended short-course ARV regimen." Tim Farley, project leader for the "Kesho Bora" study - which was conducted at five sites in Burkina Faso, Kenya and South Africa by the WHO in partnership with several other international agencies - said, "The results of this study show an almost two-fold reduction in the risk of HIV transmission during the breastfeeding period and also [show] there is no short-term toxicity (to mothers or infants)." The WHO "is reviewing its 2006 recommendations on the use of ARVs in pregnant women, including during the breastfeeding period. New guidelines are expected to be published by the end of 2009 and will take into account emerging data," Reuters reports (Roelf, 7/21). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009